

July 15, 2015

## ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2015, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2015 and its guidance for its 2016 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0951; the conference ID is 2265897. The call also may be accessed through the Investors section of the Company's website, <a href="www.immunogen.com">www.immunogen.com</a>. Following the live webcast, a replay of the call will be available at the same location through August 14, 2015.

## About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla<sup>®</sup> is the first marketed product with ImmunoGen's ADC technology. More information about the Company can be found at <a href="https://www.immunogen.com">www.immunogen.com</a>.

Kadcyla<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150715005083/en/

For Investors: ImmunoGen, Inc. Carol Hausner, 781-895-0600 info@immunogen.com or For Media: Pure Communications, Inc. Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media